These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30602198)

  • 1. Disturbed Laminar Blood Flow Causes Impaired Fibrinolysis and Endothelial Fibrin Deposition In Vivo.
    Glise L; Larsson P; Jern S; Borén J; Levin M; Ny T; Fogelstrand P; Bergh N
    Thromb Haemost; 2019 Feb; 119(2):223-233. PubMed ID: 30602198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproic acid selectively increases vascular endothelial tissue-type plasminogen activator production and reduces thrombus formation in the mouse.
    Larsson P; Alwis I; Niego B; Sashindranath M; Fogelstrand P; Wu MC; Glise L; Magnusson M; Daglas M; Bergh N; Jackson SP; Medcalf RL; Jern S
    J Thromb Haemost; 2016 Dec; 14(12):2496-2508. PubMed ID: 27706906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits.
    Krishnamurti C; Young GD; Barr CF; Colleton CA; Alving BM
    J Lab Clin Med; 1991 Dec; 118(6):523-30. PubMed ID: 1744501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
    Kawakami K; Takahashi A; Yoshimoto T
    No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
    Graham DA; Huang TC; Keyt BA; Alevriadou BR
    Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clot uptake of labeled active and inhibited tissue plasminogen activator.
    Lavie E; Bitton M; Shalev J; Weininger J; Abrashkin S; Varga E; Lubin E; Azoury R
    Biochim Biophys Acta; 1989 Apr; 991(1):62-7. PubMed ID: 2496763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
    van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
    Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion.
    Schoots IG; Levi M; van Vliet AK; Declerck PJ; Maas AM; van Gulik TM
    Thromb Haemost; 2004 Mar; 91(3):497-505. PubMed ID: 14983225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clot penetration and retention by plasminogen activators promote fibrinolysis.
    Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
    Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the role of coagulation and fibrinolysis in atherosclerosis.
    Juhan-Vague I; Collen D
    Ann Epidemiol; 1992 Jul; 2(4):427-38. PubMed ID: 1342293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrin-specific thrombolytic agents.
    Collen D
    Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What drives "fibrinolysis"?
    Medcalf RL
    Hamostaseologie; 2015; 35(4):303-10. PubMed ID: 25564072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point-of-care diagnosis and monitoring of fibrinolysis resistance in the critically ill: results from a feasibility study.
    Coupland LA; Rabbolini DJ; Schoenecker JG; Crispin PJ; Miller JJ; Ghent T; Medcalf RL; Aneman AE
    Crit Care; 2023 Feb; 27(1):55. PubMed ID: 36765421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.